In 2024, Portugal leads global diabetes medicine sales per capita at $106.2, followed by Canada at $101.1. Spain ($83.4) and Sweden ($42.8) also show significant sales. Noteworthy increases from 2023 include New Zealand's surge of 20.23% and Chile's 17.57% rise. Meanwhile, Costa Rica has the lowest growth at 2.71%, with a per capita value of $3.2. Austria and Latvia experienced more moderate rises at 7.02% and 9.34%, respectively.
Future trends to monitor include advancements in diabetes care, increasing healthcare spending, and expanding access to new medications. Emerging markets may see accelerated growth due to rising prevalence and improved diagnosis rates.
Top countries in Diabetes Medicine Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Portugal | 106.2 | 2023 | +17.22% | +14.15% | View data |
| 2 | 2 Canada | 101.1 | 2023 | +14.63% | +13.49% | View data |
| 3 | 3 Spain | 83.4 | 2023 | +8.45% | +9.12% | View data |
| 4 | 4 Sweden | 42.8 | 2023 | +11.46% | +12.93% | View data |
| 5 | 5 Estonia | 40.7 | 2023 | +4.9% | +8.08% | View data |
| 6 | 6 Latvia | 37.5 | 2023 | +5.34% | +9.34% | View data |
| 7 | 7 Austria | 37.2 | 2023 | +5.08% | +7.02% | View data |
| 8 | 8 Chile | 31.9 | 2023 | +10.76% | +17.57% | View data |
| 9 | 9 Slovakia | 30.8 | 2023 | +3.01% | +4.85% | View data |
| 10 | 10 Australia | 29.3 | 2023 | +5.4% | +7.62% | View data |
